Back to Interventions
Substance / Medication

Flecainide acetate

SNOMED 8886003UMLS C0086303

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Supraventricular tachycardia
Ventricular tachycardia
Conduction disorder of the heart
Atrial fibrillation
Arrhythmia

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Cholesterol

LOINC 2093-3

secondary

C reactive protein

LOINC 30522-7

primary

Research Evidence

Published studies and systematic reviews

Sort:
Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial.
Rienstra Michiel, Woite-Silva Anderson C, Kuijper Aaf et al. · Europace · 2025
PMID: 40132102RCTFull text (PMC)
Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm.
Crijns Harry J G M, Elvan Arif, Al-Windy Nadea et al. · Circ Arrhythm Electrophysiol · 2022
PMID: 35196871Observational
Stability-indicating chromatographic methods for determination of flecainide acetate in the presence of its degradation products; isolation and identification of two of its impurities.
El-Ragehy Nariman A, Hassan Nagiba Y, Tantawy Mahmoud A et al. · Biomed Chromatogr · 2016
PMID: 26992079Observational
Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients.
Aliot E, De Roy L, Capucci A et al. · Ann Cardiol Angeiol (Paris) · 2003
PMID: 12710293Observational
A case of acute ventricular capture threshold rise associated with flecainide acetate.
Kang Tae Soo, Yoon Young Won, Park Sungha et al. · Yonsei Med J · 2006
PMID: 16502500Case ReportFull text (PMC)
Documentation of acute rise in ventricular capture thresholds associated with flecainide acetate.
Fornieles-Pérez Helio, Montoya-García Matilde, Levine Paul A et al. · Pacing Clin Electrophysiol · 2002
PMID: 12049386Case Report
Acute loss of capture due to flecainide acetate.
Antonelli D, Freedberg N A, Rosenfeld T · Pacing Clin Electrophysiol · 2001
PMID: 11475838Case Report
Critical Aspects in the Preparation of Extemporaneous Flecainide Acetate Oral Solution for Paediatrics.
Casiraghi Antonella, Centin Giorgio, Selmin Francesca et al. · Pharmaceutics · 2021
PMID: 34834378OtherFull text (PMC)
The Effects of Flecainide Acetate on Inflammatory-Immune Response in Lipopolysaccharide-Stimulated Neutrophils and on Mortality in Septic Rats.
Chung Shi Young, Kim Jinyoung, Bae Hong Bum et al. · Acute Crit Care · 2018
PMID: 31723857OtherFull text (PMC)
Accelerated conversion of atrial fibrillation to normal sinus rhythm by pulmonary delivery of flecainide acetate in a porcine model.
Verrier Richard L, Bortolotto Alexandre L, Silva Bruna A et al. · Heart Rhythm · 2018
PMID: 29958990Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Cardiovascular Disease Physician

Internal Medicine — Cardiovascular Disease

NUCC 207RC0000X
Clinical Cardiac Electrophysiology Physician

Internal Medicine — Clinical Cardiac Electrophysiology

NUCC 207RC0001X
Find a Provider

Health Goals

Goals connected through associated conditions

Improve Heart Health

Quick Facts

Type
Substance / Medication
Fully Specified Name
Flecainide acetate (substance)
SNOMED CT
8886003
UMLS CUI
C0086303

Clinical Data

This intervention maps to 10 entities in the Healos knowledge graph.

5
Conditions
2
Biomarkers
2
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.